Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07437872 · ClinicalTrials.gov registry record · NA
Testing Mechanisms of Virtual Reality Exposure Therapy for Social Anxiety
A NA study of no Interaction VRET and Scripted Interactions VRET, sponsored by Palo Alto University.
- Recruiting
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT07437872: Recruiting NA study of no Interaction VRET and Scripted Interactions VRET, sponsored by Palo Alto University.
NCT07437872 is a NA study of no Interaction VRET and Scripted Interactions VRET that is actively recruiting participants, run by Palo Alto University. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07437872, a NA study of no Interaction VRET and Scripted Interactions VRET, is actively recruiting participants, sponsored by Palo Alto University.
- RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test mechanisms and processes of virtual reality and augmented reality exposure therapy for social anxiety. There is substantial evidence that virtual reality exposure therapy is an effective treatment for social anxiety. However, it can be difficult to access treatment that needs to be conducted in person. Tests of self-guided (without therapist assistance) virtual reality exposure therapy have had mixed efficacy and tests of augmentation offer an important method to optimize brief interventions. The study objectives are to test a wide range of possible mechanisms and approaches (ranging from single sessions in person to remotely conducted virtual reality exposure therapy) in order to advance the field. The broadness of the proposed research is to provide multiple avenues for inquiry per discussion with IRB chair Dr. Kuo. Depending on the specific line of inquiry some variations will be documented (e.g., multiple consent forms for answering different sub questions of the primary questions listed below).
Primary Outcome
The Liebowitz Social Anxiety Scale Self Report Version is a 48-item self-report measure of fear and avoidance concerning social interactions and performance situations (e.g., telephoning in public, talking to people in authority). The range of scores is 0-144; higher scores are worse.
Conditions Studied
Interventions
- BEHAVIORAL ExpandXR
Study Locations (1)
California
- Palo Alto University Mountain View Campus - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-02-24 |
| Est. Completion | 2028-03-01 |
| Phase | NA |
What NCT07437872 shows while recruiting
NCT07437872 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with no Interaction VRET appearing as the primary indexed condition, and to 1 intervention - of which ExpandXR is the first listed.
NCT07437872 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07437872 about?
NCT07437872 is a clinical study titled "Testing Mechanisms of Virtual Reality Exposure Therapy for Social Anxiety". The purpose of this study is to test mechanisms and processes of virtual reality and augmented reality exposure therapy for social anxiety. There is substantial evidence that virtual reality exposure therapy is an effective treatment for social anxiety. However, it can be difficult to access treatme...
What is the current status of trial NCT07437872?
This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2026-02-24. Estimated completion is 2028-03-01.
What conditions does trial NCT07437872 study?
This clinical trial studies the following conditions: no Interaction VRET, Scripted Interactions VRET, Fully Customized Interactions VRET.
What interventions are being tested in trial NCT07437872?
The interventions under investigation include: ExpandXR (BEHAVIORAL).
Who is sponsoring clinical trial NCT07437872?
This trial is sponsored by Palo Alto University, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07437872 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07437872's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI